NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25 avr. 2024 08h35 HE
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
22 avr. 2024 08h00 HE
|
Elevai Labs Inc.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
18 mars 2024 08h30 HE
|
Elevai Labs Inc.
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
08 mars 2024 16h05 HE
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone’s Intellectual Property Portfolio Expands
20 févr. 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
14 févr. 2024 16h20 HE
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
24 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
17 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
16 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology